Abstract
The immune systems of post-pubescent males and females differ significantly with profound consequences to health and disease. In many cases, sex-specific differences in the immune responses of young adults are also apparent in aged men and women. Moreover, as in young adults, aged women develop several late-adult onset autoimmune conditions more frequently than do men, while aged men continue to develop many cancers to a greater extent than aged women. However, sex differences in the immune systems of aged individuals have not been extensively investigated and data addressing the effectiveness of vaccinations and immunotherapies in aged men and women are scarce. In this review, we evaluate age- and sex hormone-related changes to innate and adaptive immunity, with consideration about how this impacts age- and sex-associated changes in the incidence and pathogenesis of autoimmunity and cancer as well as the efficacy of vaccination and cancer immunotherapy. We conclude that future preclinical and clinical studies should consider age and sex to better understand the ways in which these characteristics intersect with immune function and the resulting consequences for autoimmunity, cancer, and therapeutic interventions.
Introduction
In developed countries, the population is aging, with the number of people over the age of 65 doubling in size from 2012 to 2050 (1). In developed and even developing countries, lifespan is longer for women than men (2, 3). Both sex (i.e., biological differences between males and females) and gender (i.e., social or cultural norms that define masculine and feminine) contribute to male–female differences in mortality rates among individuals 65 years and older. Why and how the sexes differ in the incidence and progression of immune-related diseases that are either specific to advanced age or that worsen with age, such as particular infections, autoimmune disease, and cancer, has not been well studied.
Aging is associated with the development of chronic inflammation and a general reduction in immune function. The effect of sex on immune function during the aging process has not been well studied. But, some studies indicate that the innate immune system of aged females may be more inflammation-prone when compared with aged males. However, aging of the adaptive immune system may occur at a faster rate in men, when compared with women. Several diseases that are associated with age are also sensitive to changes in the immune system. Therefore, herein, we will discuss the effects of age and sex on the innate and adaptive immune systems and the contribution of sex hormones to these effects. We will also examine the functional consequences of age- and sex-related changes to immunity in the contexts of vaccination, autoimmunity, cancer, and cancer immunotherapy. We conclude that sex and age should be considered in future clinical and preclinical studies to improve our understanding and treatment of age-associated diseases.
Age-Related Changes in Immune Function
With age, there is a decline in the functioning of the immune system (4) that has, until recently, been assumed to occur equally in males and females. “Inflammaging,” as defined by aberrant chronic low-grade inflammatory responses, is one of the most well-characterized attributes of an aging immune system (5). The activity of dendritic cell (DC) subsets, macrophages, and neutrophils, each of which are associated with inflammation, also become altered with age (6–9). Inflammatory responses are necessary to clear pathogens and repair tissues; chronicity of inflammatory responses, however, can contribute to tissue damage and disease, especially among aged individuals. Similarly, adaptive immunity becomes less functional with age (10, 11). Reductions in lymphopoeisis along with exposure to pathogens throughout the lifespan contribute to reduced numbers of naïve lymphocytes with increased proportions of memory and memory-like lymphocytes that are associated with less robust functional outcomes (12, 13). Overall, age-associated changes to the functions of innate and adaptive immune cells (summarized in Figure 1) likely contribute to increased risk of specific autoimmune diseases and cancer, as well as altered vaccine and cancer immunotherapy efficacy.
Figure 1
Age-Related Changes in Innate Immunity
Aging is associated with the secretion of pro-inflammatory cytokines, such as TNF, IL-6, and IL-1β, the cellular source of which has not yet been clearly identified (14). Innate immune cells, including DCs, neutrophils, and macrophages, become less functional and, paradoxically, more inflammatory with age. It has been difficult to determine whether systemic inflammation causes innate cell dysfunction or vice versa. Recent evidence discussed below suggests that inflammaging may alter the development and signaling potential of innate cells, contributing to inflammation in the absence of infection and, at the same time, a reduced ability to clear infections (15–17). Together, the elevated levels of inflammatory cytokines and diminished ability to resolve infections or local inflammation likely contribute to less functional innate responses to vaccination and increased risk of certain autoimmune diseases.
The number and proportion of plasmacytoid DCs declines during healthy aging, while frailty appears to be associated with reduced numbers of conventional DCs (8). Regardless of their number, conventional DCs from aged mice and humans migrate, phagocytose, express costimulatory molecules, secrete cytokines, and prime T cells poorly in response to exogenous antigens when compared with DCs from young conspecifics (6, 18–32). At least some of these defects appear to be cell intrinsic and related to the altered expression of toll-like receptors (TLRs) and dysregulated downstream signaling [reviewed in Ref. (33)].
Neutrophils from aged individuals have defects in accurately migrating to inflamed tissues, phagocytosing microbes, producing reactive oxygen species (ROS), and capturing microbes using neutrophil extracellular traps (9, 34–38). Like neutrophils, many functions of macrophages are negatively affected by aging including migration, phagocytosis, production of ROS and cytokines, and expression of major histocompatibility complex class II and costimulatory molecules (15, 39–43). Studies examining the cytokine response of monocytes isolated from older patients have yielded mixed results, likely due to differences in health status, isolation techniques, assay conditions, and stimuli between studies [reviewed in Ref. (33)]. Some studies have revealed a diminished ability of aged monocytes and macrophages to secrete pro-inflammatory cytokines robustly after exposure to pathogens, LPS, or other TLR ligands (44–50). Chronic exposure to inflammatory cytokines such as IL-6 and TNF-α and dysregulated expression and/or function of TLRs have been discussed as possible causes (44, 45, 48).
Several recent reports have suggested that at least in mice, inflammaging may precede and perhaps even cause dysregulation of innate immune cells, which may further contribute to inflammation. For example, aging is also associated with increased proportions of pro-inflammatory monocytes of non-classical and intermediate phenotypes (i.e., CD14+CD16+ or CD16++ in humans and Ly6Chi in mice) that are less mature, poorer phagocytes, and may be more prone to secreting pro-inflammatory cytokines at baseline and in response to stimuli (15–17, 47, 51). In mice, aged Ly6Chi monocytes both contribute to age-associated inflammation and are impaired by the inflammation with negative consequences for bacterial clearance (16). Circumstantial evidence indicates that in humans, premature migration of intermediate phenotype monocytes (CD14++CD16+) is driven by TNF-α-mediated upregulation of CCR2, as also occurs in mice (16), and may contribute to worsened disease outcomes in rheumatoid arthritis patients (52, 53).
Additional age-related changes to monocyte function may contribute to increased susceptibility to infection concomitant with a reduced ability to resolve inflammation. For example, the production of specialized pro-resolving mediators, including lipid signaling molecules produced by macrophages and monocytes, is reduced in aged mice and is associated with delayed resolution of acute inflammation (54). In addition, aged macrophages isolated from mice and humans phagocytose infectious agents and apoptotic cells less efficiently than young macrophages (15, 40, 55–59). The phagocytosis of infectious agents and apoptotic cells by macrophages is important for resolution of inflammation and restoration of tissue integrity, which is reduced with aging.
Age-Related Changes in Adaptive Immunity
Aging is accompanied by a decline in the production of new lymphocytes as well as increased expansion and survival of antigen-specific memory lymphocytes in mice and humans (60–72). Despite reduced lymphopoeisis (73–76), the overall number of peripheral lymphocytes is maintained in aged mice (11) and humans [reviewed in Ref. (77)], with the exception of peripheral B cell numbers being reduced in older humans (78, 79). The diminished functionality of older adaptive cells may be related to age-associated changes in lymphocyte development.
The ability of aged T cells to proliferate robustly, differentiate appropriately, and generate memory is generally diminished (10, 12, 13, 80–85). However, all T cell functions are not impaired by aging. T regulatory (Treg) and, in some cases, T helper 17, cells increase in number and/or function with age (81, 85–93). It was recently proposed that naïve T cells produced in neonates form a long-lived, self-renewing population of “incumbent” naïve T cells that are resistant to replacement by T cells produced after the neonatal period (94). It is conceivable that accumulated damage in these long-lived incumbents may contribute to reduced naïve T cell function with age. In addition, accelerated homeostatic proliferation, as may be more likely to occur in aged individuals (95, 96), is associated with the selection of autoreactive T cells, at least in mice (97–99) and may also affect overall T cell functionality.
Changes in aged naïve T cell function likely contribute to defective memory generation and also partially explain the observation that antibodies elicited from older mice and humans are less protective compared with those from the young individuals (100–106), even though serum IgG levels increase with age in both mice and humans (107, 108). In addition, aged B cells demonstrate intrinsic defects in germinal center formation, class switch recombination, and somatic hypermutation (109–112). Aged B cells from mice and humans do not sufficiently upregulate expression of activation-induced cytidine deaminase (AID, the enzyme required for class switch recombination and somatic hypermutation) due to diminished levels of the necessary transcription factor (107, 110, 113, 114). With age, there are also more long-lived antigen-experienced B cells, including age-associated B cells (ABCs) (60, 115–120). ABCs are responsive to TLR7 and 9 ligands but less so to T cell-dependent signals and have been hypothesized to be generated by nucleic acid-containing antigens during inflammation (118, 121).
Sex Differences in Age-Related Changes in Immune Function
Both innate and adaptive immune responses differ between males and females at young and advanced ages (summarized in Table 1). Most published studies of immune system differences between the sexes utilize young adults and do not address whether sex differences in immune function change with aging. Overall, the available data indicate that young adult females demonstrate a more reactive, inflammatory profile when compared with young adult males. A clear consensus has not emerged regarding whether these sex differences are maintained during advanced age, but the immune systems of aged women on hormone replacement therapy (HRT) and monocytes isolated from aged women, regardless of HRT status, appear to remain skewed toward an inflammatory phenotype (16, 122–124). The currently available data also indicate that the adaptive immune response of aged women may be preserved to a greater extent than in aged men. These studies are discussed in more detail below.
Table 1
 Dendritic cells |  Monocytes and macrophages |  Granulocytes |  Innate lymphoid cells |  Natural killer cells |  B cells |  T cells | |
|---|---|---|---|---|---|---|---|
| Young adults | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | |
| TLR7 activity (H) | Activation (M) | Phagocytic capacity (M) | Type 2 cytokine levels upon stimulation (M) | B cell numbers (H, M) | CD4+ T cell count (H, M) | ||
| Type 1 IFN activity (H) | Phagocytic capacity (M) | Neutrophil count (M) | Antibody production (H, M) | CD4+/CD8+ T cell ratio (H) | |||
| IL-10 production (M) | Nitric Oxide production post stimulation (H, R, M) | % switched memory B cells (H) | Activated T cell count (M) | ||||
| M2 polarization (M) | T cell proliferative capacity (M) | ||||||
| Cytotoxic T cell activity (H) | |||||||
| ♂ > ♀ | ♂ > ♀ | ♂ > ♀ | ♂ > ♀ | ♂ > ♀ | ♂ > ♀ | ||
| IL-10 production (R, H) | TLR4 expression (M) | NK cell activity (R) | |||||
| Pro-inflammatory cytokine production (M) | Neutrophil attractant chemokines (R) | Type 2 ILC count (H) | ♀ = ♂ | CD8+ T cell count (M) | |||
| M1 polarization (M) | TLR9 expression (M) | IL-13 production upon stimulation (M) | NK cell count (H) | Treg count (M) | |||
| Aged adults | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | ♀ > ♂ | ||
| Nitric oxide synthesis (H) | CD62L, CD115 (H) expression | NK cytotoxicity (H) | Antibody production (H) | CD3+ T cell count (H) | |||
| Mammalian family of mitogen-activated protein kinases (MAPK) signaling (H, M) | Immunosurveillance (H) | Age-associated B cell count (H, M) | CD4+ T cell count (P) | ||||
| CD4+/CD8+ T cell ratio (P) TH1 response (M) | |||||||
| IL-15 production (H) | TH1 response (M) | ||||||
| ND | ND | Naïve CD8+ T effector memory cells (p) | |||||
| T cell proliferative capacity (H, P) | |||||||
| ♂ > ♀ | ♂ > ♀ | ||||||
| CD38 expression (H) | CD8+ T cell count (P) | ||||||
| Non-classical monocyte count (H) | |||||||
Sex differences in innate and adaptive immune responses in young and aged individuals.
Sex Differences in Age-Related Changes to Innate Immunity
As mentioned above, at least among young adults, innate immune responses differ between the sexes. Using murine model systems, it has been shown that the activity of pattern-recognition receptors, production of inflammatory proteins (e.g., IFN-α, IFN-γ, and TNF-α), activity of macrophages, including antigen presentation and phagocytosis is higher in females than males (132–138). Studies evaluating innate immune system differences between the sexes are scarce. But, at least one small study demonstrated that aged females display elevated concentrations of inflammatory proteins compared with males, as also occurs in young men and women (139). Several cytokines show differential levels in circulation between the sexes. For example, IL-15 is an important homeostatic cytokine in T cells, NK cell, and memory responses and is significantly upregulated in aged females when compared with age-matched males (122, 123). However, upon exclusion of individuals on HRT, such differences between sexes were no longer significant (122). After menopause, there is a significant increase in IL-1, IL-6, and TNFα, and reduction in IFNγ in women (140, 141). Testosterone has an immunosuppressive effect on inflammatory cytokine production and its decline with aging is associated with an increase in serum soluble IL-6 receptor (142). Monocyte and leukocyte subpopulations in aged males and females express different levels of receptors; males show higher CD38 expression, whereas females show higher CD62L and CD115 expression, indicating differences in their activation profiles and memory phenotypes (124). Sex differences among monocyte subsets have also been reported in aged individuals. Aged females have a higher proportion of intermediate (CD14hiCD16low) monocytes than similarly aged males, which have been shown to exhibit pro-inflammatory tendencies, as mentioned above (16, 124). Finally, NK cells in older women are superior at cancer immunosurveillance when compared with cells in older men. CD56dim NK cells are more cytotoxic and more responsive to leukemic cells in aged females compared with aged males, which may explain the higher incidences of cancer in aged men compared with women in populations (143).
Sex Differences in Age-Related Changes to Adaptive Immunity
Both humoral and cell-mediated immune responses to antigenic stimulation, vaccination, and infection are typically higher among females than males (135). Females also typically demonstrate higher basal levels of immunoglobulin (144) and higher antibody responses to viruses and vaccine antigens than males at any age (145–147). Among humans, absolute CD3+ T cell counts, frequencies of CD4+ T cells, helper T cell type 1 responses, and the ratio of CD4+:CD8+ T cells are all lower in men when compared with women (148–151).
As already mentioned, sex or gender has not traditionally been considered when evaluating age-related changes to the adaptive immune system [reviewed in Ref. (14)]. However, several groups have reported that in some ways, aging occurs at an accelerated rate in males when compared with females. For example, aged males experience a more dramatic decrease in total numbers of T and B cells and a larger increase in senescent CD8+ T effector memory cells that re-express the naïve marker CD45 RA (TEMRA) when compared with females (14, 150, 152–154). In addition, a greater proportion of aged males than females demonstrate an inverted CD4:CD8 T cell ratio, an age-related phenotype that is also associated with decreased levels of CD19+ B cells and CD8+CD28− senescent T cells (152). Also, the capacity of T cells to proliferate is preserved to a greater extent in women than men throughout the aging process (154), which may be an important consideration for infectious diseases and related interventions. On the other hand, transcriptional analyses of peripheral blood mononuclear cells from aged males and females revealed several pro-inflammatory pathways, including NF-κB signaling, NO synthesis, and p38 MAPK signaling, that are reduced to a greater extent in aged females than aged males (123). Moreover, aged females have greater numbers of ABCs than young females and males of all ages (118, 119).
The Impact of Sex Hormones on Age-Related Changes in Immune Responses
Immunological differences between males and females can arise from diverse mechanistic causes, including genetic, hormonal, and even microbiome differences between the sexes. Partly because of the ease of measuring and manipulating, sex steroids, particularly testosterone, estradiol, and progesterone, have been most well characterized as mediators of sex differences in immune responses and are the focus of this review. Sex steroids affect immune function by binding to specific hormone receptors expressed in diverse immune cells (155). With age, the hormonal milieu of females and even males changes, with an overall decline in concentrations of estrogens and progesterone in females and testosterone in males (156–158). We hypothesize that the changes in sex steroid concentrations and sex steroid receptor signaling with age may contribute to age-associated dysregulation of immune function (159). Although this has been considered in females through the comparison of pre- and post-menopausal women, few studies have considered hormonal changes in men as playing a role in age-associated changes in immune responses. Among women, with menopause, numbers of B and T cells are reduced and concentrations of IL-1β, IL-6, and TNF-α are significantly increased (141, 160, 161). Treatment of post-menopausal females with hormone replacement therapies that contain formulations of estrogen affects immune function by increasing circulating numbers of B cells and reducing baseline concentrations of pro-inflammatory cytokines when compared with post-menopausal females not on HRT (140, 161). Whether testosterone replacement therapy affects immune responses in aged human males has not been reported. In non-human primates, aged male rhesus macaques have lower frequencies of naïve CD4+ and CD8+ T cells than young males, with supplementation of androgens in aged male resulting in increased numbers of naïve T cells presumably by increasing thymic output (162). Whether treatment of aged individuals with hormone replacement therapies affects the outcome of vaccines or immunotherapies in either females or males has not been reported.
Studies in mice and humans have shown that the diversity and richness of intestinal microbiota differs between males and females after puberty, presumably due testosterone, but not estrogen (163–168). Moreover, in mice, exposure to specific microbiota at early ages also results in elevated levels of testosterone (164). Thus, testosterone appears to influence the composition of the gut microbiome and, in a positive feedback loop, specific microbes elevate testosterone levels (164). Sex-specific enrichment for particular microbes is likely to have significant influence on sex-specific immune function since particular commensals and their metabolites can dramatically modify host innate and adaptive immune function [reviewed in Ref. (169)] with serious consequences for autoimmunity, vaccine efficacy, cancer, and cancer immunotherapy [reviewed in Ref. (170, 171)]. The composition and richness of commensal microbiota is sensitive to many environmental factors as well, including diet. Importantly, dietary effects on the relative abundance of specific microbial taxa also differ by sex in humans and, to a lesser extent, in mice (172). Sex-specific differences in microbial composition and richness have also been reported in humans over the age of 60 and aged mice (163, 165, 166, 173).
Functional Significance of Sex Differences in Immune Responses among Aged Individuals
Vaccine Responses
In aged individuals, sex differences in antibody responses to vaccines are less consistent and depend on the vaccine antigen. The influence of sex and age has been most well studied for inactivated influenza virus vaccines as they are administered annually. For example, among individuals 65+ years of age, hemagglutinin inhibition antibody titers to both the standard and high dose seasonal trivalent inactivated influenza (TIV) vaccine are significantly higher in aged females when compared with males (174). Because influenza virus vaccines are available on an annual basis, a greater number of exposures (i.e., the behavioral act of seeking out vaccination) combined with the slower decline in immunity that occurs in aged females (see above) may contribute to sex differences in the antibody response to the TIV vaccine. By contrast, aged males have higher antibody responses to the tetanus diphtheria and pertussis (Td/Tdap) vaccines as well as the 7-valent and 23-valent pneumococcal vaccines (175–179). There is an insufficient number of studies from which to draw conclusions to understand why sex differences in vaccine-induced antibody responses are higher in aged females than males for a viral vaccine (i.e., the TIV vaccine), but lower in females than males for bacterial vaccines (i.e., the Td/Tdap and pneumococcal vaccines). If more vaccine studies were designed with a priori hypotheses about sex differences in vaccine-induced immunity, then we could begin to understand discrepancies in the findings following exposure to differential vaccine antigens.
Adverse reactions to vaccines, which are typically mild to moderate, can include both local (i.e., at the site of vaccination) and systemic reactions. Adverse reactions are reported by aged women more than their male counterparts in response to the seasonal and pandemic influenza vaccines (180–188), the pneumococcal vaccines (189, 190), the herpes zoster vaccine (191), or the tetanus and pertussis vaccines (192–194). While the types of adverse reactions experienced by aged males and females are typically similar, the proportion of females reporting redness, swelling, and injection site pain locally as well as headache, fever, chills, joint or muscle pain, headache, back and abdominal pain, or hypersensitivity reactions systemically is often greater than males. The prevailing hypothesis for differences in adverse reactions among aged males and females is that this reflects a gender-based reporting bias.
The efficacy of a vaccine is measured by the percent reduction in disease incidence in a vaccinated population (195). Sex-specific differences in vaccine efficacy are rarely considered, with most data coming from studies of influenza vaccines. Vaccine efficacy, which is defined by hospitalization and mortality rates post-vaccination, is lower in aged females than males, at least for the influenza vaccine (196–200). For other vaccines that are not administered annually, including the pneumococcal and herpes zoster vaccines, there are considerably less data. Overall, the efficacy both the herpes zoster and pneumococcal vaccines tends to be higher in aged females than their male counterparts (191, 201, 202).
Autoimmunity
Most autoimmune patients are diagnosed between the ages of 20 and 60 years (203). For those whose autoimmune disease develops later, the disease tends to be milder and more easily controlled (203). Women are disproportionately affected by autoimmune disease, and this holds true for several autoimmune diseases with late-adult onset as well, including rheumatoid arthritis, polymyalgia rheumatica, and giant cell arteritis (Table 2). Regardless of the age of onset, the cellular and molecular basis of autoimmunity is complicated and distinct for each specific disease [reviewed in Ref. (204)]. Here, we focus on the impact of age and sex on autoimmune conditions with late onset.
Table 2
| Autoimmune disease | Autoimmune target | Mean age of onset (range) years | Female:male ratio | Reference |
|---|---|---|---|---|
| Mid-adult onset | ||||
| Multiple sclerosis | Myelin sheath | 37 (25–45) | 1.8:1 | (205) |
| Myasthenia gravis | Neuromuscular junction | 40 | 2.7:1 | (205) |
| Systemic lupus erythematosus | Nuclear contents (systemic) | 40 (30–50) | 9:1 | (205, 206) |
| Neuromyelitis optica | Optic nerve/spinal cord | 32.6–45.7 | 2.4:1 ratio highest after age 65 | (207, 208) |
| Graves’ disease | Thyroid | 48 | 7.3:1 | (205) |
| Systemic sclerosis | Connective tissue (systemic) | 50 (35–65) | 11.5:1 | (209) |
| Late-adult onset | ||||
| Granulomatosis with polyangiitis (GPA) (formerly Wegener’s granulomatosis) | Cytoplasmic contents of neutrophils (systemic, vascular) | 55 (40–70) | 1:1 M > F after age 70 | (205) |
| Rheumatoid arthritis | Joints | 58 (42–74) | 3:1 | (210) |
| Polymyalgia rheumatica | Selected muscle groups | 70–80 | 2.3:1 | (211) |
| Giant cell arteritis | Vascular system | 70–80 | 2.3:1 | (211) |
The female-to-male patient ratio for select mid-adult and late-adult onset autoimmune diseases.
Although several theories have been proposed to explain sex differences in the cellular and molecular basis of aging [reviewed in Ref. (212)], perhaps most relevant to the sex-specific development of autoimmunity in the aged is that estrogen upregulates the activity of several antioxidant systems (213, 214). Dramatic loss of estrogen (such as during menopause) could be expected to result in increased cell death due to unchecked ROS-induced DNA damage. Indeed, fewer lymphocytes are detected in the blood of post-menopausal women compared with younger women (160, 215) and T cell apoptosis increases after natural or surgical menopause (216). This could especially explain increased female incidence of autoimmune diseases that may occur as a result of lymphopenia-induced homeostatic proliferation in the aged, although more studies are needed to test this hypothesis.
In mice, lymphopenia and the subsequent homeostatic proliferation of lymphocytes has been shown to contribute to the development of autoimmunity in many contexts [reviewed in Ref. (217)]. Certainly, there is an association between autoimmunity and lymphopenia in humans, but a strong case has not been made that lymphopenia is causative, or even occurs prior to, the onset of autoimmunity (218–224). However, evidence gathered by the laboratories of Goronzy et al. support a model whereby accelerated T cell loss in the aged, either due to telomerase deficiency, disruption to DNA repair responses, or menopause, may be sufficient to enable autoreactive T cells already present in the pool to respond to low-affinity self-antigens in rheumatoid arthritis patients [reviewed in Ref. (225)]. First, there is evidence of accelerated aging, or increased homeostatic proliferation in RA patients. The telomeres of naïve and memory T cells isolated from RA patients are shorter than age-matched controls (226) and T cell receptor diversity is reduced as well (227). Moreover, T cells from RA patients are more prone to apoptosis and are less capable of repairing dsDNA breaks (228). Finally, end-differentiated effector T cells that may be the consequence of homeostatic proliferation appear to be major participants in late onset autoimmune pathogenesis (229–232).
Cancer
Sex and age influence cancer incidence and mortality, but the specific effects vary by cancer type. It is widely accepted that the probability of developing cancer increases with age (233). Although few studies have examined cancer incidence in those with very advanced age, it seems that cancer prevalence actually declines for those over the age of 85 (234, 235). There is some evidence to indicate that tumors may also be generally less aggressive in the extremely aged (236). Indeed, breast and prostate cancer patients over the age of 55 are more likely to develop tumors with characteristics associated with favorable treatment and/or survival outcomes (237, 238). However, it is not clear that tumors associated with other types of cancer, including bladder cancer, lung cancer, and acute myeloid leukemia, are indolent in older patients (239–242).
Overall, young men generally experience higher rates of cancer incidence and mortality than women (243–245). At advanced ages, men continue to experience higher incidences of most types of cancers, especially colorectal cancer, when compared with women (245, 246), but relative cancer mortality rates between older men and women differ by the particular cancer. Mortality differences between men and women diminish with age (especially after the age of 70) for colorectal cancer, stomach cancer, and leukemia (247). However, the male-to-female mortality ratio for brain cancer and myeloma decreases after middle age, but then increases again after the age of 70 (247).
The loss of sex hormones (especially due to menopause in women), age-associated immunosuppression, and chronic inflammation may contribute to sex- and age-specific patterns of cancer incidence and mortality. Indeed, the male preponderance of cancer incidence and mortality before menopause has been at least partially attributed to the protective effect of estrogen (248), presumably due to its ability to enhance immunosurveillance, as well as tissue-specific effects (249, 250). Purim et al. suggests that it takes 20–25 years for some cancers (such as colorectal) to develop and since changes in sex-specific incidence ratios for those cancers occur approximately 25 years after menopause, the loss of estrogens at approximately age 55 contributes to increased female cancer incidence after the age of 80 (246). On the other hand, age- and sex-related diminishment of the effectiveness of the immune system may not contribute a great deal to increased cancer incidence in the aged, since the types of cancers observed in the aged are not the same of those observed in immunocompromised patients. HIV-induced immunodeficiency is associated with lymphoma and Kaposi’s sarcoma, while most age-related malignancies in the aged are carcinomas (251). Finally, older persons with chronic inflammation may demonstrate increased risk of cancer, as it is clear that inflammation induced by viruses, bacteria, tobacco smoke, and obesity increases cancer risk (252–255). Overall, more studies are certainly warranted to better understand the factors that contribute to cancer incidence and mortality in older men and women.
Cancer Immunotherapy
Cancer immunotherapy trials typically involve younger patients with no co-morbidities, even though these characteristics are not representative of most cancer patients (256). This is particularly important because the effectiveness and dose of any particular immunotherapy is likely to be affected by age-associated changes in immunity and metabolism (256). In addition, few clinical trials are designed to compare the efficacy and safety of cancer immunotherapies between women and men of any age (257). The currently available data regarding the sex- and age-specific effectiveness of several immunotherapies are discussed below.
Checkpoint blockade therapies in young or middle-aged men and women appear to be beneficial, but the benefits may be stronger in men (258–261). Blockade of PD1/PDL1 with nivolumab was more effective in male melanoma and renal cell carcinoma patients than in female patients (258, 260). However, these studies were not designed to compare efficacy in male versus female patients, and the sample size for female patients was small. Preclinical studies of anti-PDL1 treatment revealed that melanoma tumor growth was more robustly reduced in female mice when compared with males (262). Estrogen upregulates PD-1 on Tregs and Teffs. The authors speculated that anti-PDL1 treatment was more effective in females because of the greater contribution of PD-1 to Treg suppression of antitumor responses in females (262). In addition, as mentioned above, the microbiome varies with age and sex and has recently been shown to significantly influence cancer immunotherapy success. Indeed, recent antibiotic use and the absence of specific microbial taxa correlates with reduced efficacy of PD1/PDL1 blockade and certain immune-reliant chemotherapies in both humans and mice [reviewed in Ref. (170, 263)]. Therefore, it is critical to more formally evaluate the effect of cancer immunotherapies in men and women and to assess the suitability of various cancer models for predicting the success of particular immunotherapies in the sexes.
As already mentioned, few clinical immunotherapy trials enroll patients of advanced age and studies that did include older patients reach different conclusions about the efficacy of checkpoint blockade in the aged. Meta-analyses of heterogeneous groups of cancer patients over the age of 65 or 70 treated with immune checkpoint inhibitors (biologicals targeting PD1, PDL1, or CTLA4) compared with similarly aged patients enrolled in the control arm of the studies revealed that checkpoint inhibitors reduced the risk of death by 34–37% in patients with advanced age (264, 265). Moreover, in at least one meta-analysis, the overall survival rate of patients over the age of 65 or 70 and younger patients treated with immune checkpoint inhibitors did not differ (264). However, other studies have reported significantly worse overall survival rates in patients over the age of 75 treated with checkpoint inhibitors (266). Finally, there is concern that treatment of older cancer patients with checkpoint inhibitors could actually enhance tumor growth, as occurred in one subset of cancer patients (267) or prompt immune-related adverse events, as occurs in mouse models (268).
Conclusion
For most, the aging process is accompanied by alterations in the function of the immune system. Many experience chronic inflammation and a general impairment of immune cell function. The immune systems of young men and women are quite different, and it appears that aging affects the cellular composition and function of the immune system in sex-specific ways as well. This is likely because of pre-existing differences in immunity between men and women as well as differences in how menopause and andropause unfold. Age- and sex-specific changes to immunity may have consequences for late-adult onset autoimmunity and cancer, as well as for the efficacy of vaccinations and cancer immunotherapies. However, our understanding of the ways in which sex and age intersect with immune function and the consequences of this for autoimmunity, cancer, and therapeutic interventions is severely limited by the lack of inclusion of these variables in clinical and preclinical studies. Therefore, preclinical and clinical studies related to vaccination, autoimmunity, and cancer therapies must be powered to detect sex effects, in accordance with the sex and gender equity in research (SAGER) guidelines (269). Age, sex hormone concentrations, hormone replacement therapies, and health status must be considered as well, given the known impact of these variables on immune-related conditions common in the aged (Table 3).
Table 3
| Clinical study considerations | |
|---|---|
| Age | Clearly defined age categories |
| Young: 20 to ≤45 years | |
| Old: >45 to ≤85 years | |
| Very old/elderly: >85 years | |
| Health status | Frailty: three of the five following characteristics: weight loss, weakened handgrip, exhaustion, reduced gait speed, and reduced activity |
| Concentrations of serum inflammatory proteins: IL-6, TNF-α, IL-1β, and C-reactive protein | |
| Sex hormone status | Time of menopause |
| Serum concentrations of sex hormones | |
| Hormone replacement therapy | |
Variables to consider when designing clinical studies related to immunity in the aged.
Statements
Author contributions
MB conceived of the idea for this review. MB and SK outlined the content. MB, TP, AF, and SK researched and wrote sections. All authors edited and reviewed the final draft.
Funding
The writing of this review was supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N272201400007C (SK).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
OrtmanJMVelkoffVAHoganH. An aging nation: the older population in the United States. Current Population Reports. Washington, DC: U.S. Census Bureau (2014).
2
LozanoRNaghaviMForemanKLimSShibuyaKAboyansVet alGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 380(9859):2095–128.10.1016/S0140-6736(12)61728-0
3
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 385(9963):117–71.10.1016/S0140-6736(14)61682-2
4
Castelo-BrancoCSoveralI. The immune system and aging: a review. Gynecol Endocrinol (2014) 30(1):16–22.10.3109/09513590.2013.852531
5
CannizzoESClementCCSahuRFolloCSantambrogioL. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics (2011) 74(11):2313–23.10.1016/j.jprot.2011.06.005
6
AgrawalATayJTonSAgrawalSGuptaS. Increased reactivity of dendritic cells from aged subjects to self-antigen, the human DNA. J Immunol (2009) 182(2):1138–45.10.4049/jimmunol.182.2.1138
7
CananCHGokhaleNSCarruthersBLafuseWPSchlesingerLSTorrellesJBet alCharacterization of lung inflammation and its impact on macrophage function in aging. J Leukoc Biol (2014) 96(3):473–80.10.1189/jlb.4A0214-093RR
8
JingYShaheenEDrakeRRChenNGravensteinSDengY. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol (2009) 70(10):777–84.10.1016/j.humimm.2009.07.005
9
WenischCPatrutaSDaxbockFKrauseRHorlW. Effect of age on human neutrophil function. J Leukoc Biol (2000) 67(1):40–5.10.1002/jlb.67.1.40
10
HaynesLMaueAC. Effects of aging on T cell function. Curr Opin Immunol (2009) 21(4):414–7.10.1016/j.coi.2009.05.009
11
MillerJPCancroMP. B cells and aging: balancing the homeostatic equation. Exp Gerontol (2007) 42(5):396–9.10.1016/j.exger.2007.01.010
12
HaynesLEatonSMBurnsEMRandallTDSwainSL. CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly. Proc Natl Acad Sci U S A (2003) 100(25):15053–8.10.1073/pnas.2433717100
13
KangIHongMSNolascoHParkSHDanJMChoiJYet alAge-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol (2004) 173(1):673–81.10.4049/jimmunol.173.1.673
14
Gubbels BuppMR. Sex, the aging immune system, and chronic disease. Cell Immunol (2015) 294(2):102–10.10.1016/j.cellimm.2015.02.002
15
HearpsACMartinGEAngelovichTAChengWJMaisaALandayALet alAging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell (2012) 11(5):867–75.10.1111/j.1474-9726.2012.00851.x
16
PuchtaANaidooAVerschoorCPLoukovDThevaranjanNMandurTSet alTNF drives monocyte dysfunction with age and results in impaired anti-pneumococcal immunity. PLoS Pathog (2016) 12(1):e1005368.10.1371/journal.ppat.1005368
17
VerschoorCPJohnstoneJMillarJParsonsRLelicALoebMet alAlterations to the frequency and function of peripheral blood monocytes and associations with chronic disease in the advanced-age, frail elderly. PLoS One (2014) 9(8):e104522.10.1371/journal.pone.0104522
18
AgrawalAAgrawalSCaoJNSuHOsannKGuptaS. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol (2007) 178(11):6912–22.10.4049/jimmunol.178.11.6912
19
MorettoMMLawlorEMKhanIA. Aging mice exhibit a functional defect in mucosal dendritic cell response against an intracellular pathogen. J Immunol (2008) 181(11):7977–84.10.4049/jimmunol.181.11.7977
20
Stout-DelgadoHWYangXWalkerWETesarBMGoldsteinDR. Aging impairs IFN regulatory factor 7 up-regulation in plasmacytoid dendritic cells during TLR9 activation. J Immunol (2008) 181(10):6747–56.10.4049/jimmunol.181.10.6747
21
PereiraLFde SouzaAPBorgesTJBonorinoC. Impaired in vivo CD4+ T cell expansion and differentiation in aged mice is not solely due to T cell defects: decreased stimulation by aged dendritic cells. Mech Ageing Dev (2011) 132(4):187–94.10.1016/j.mad.2011.03.005
22
LiGSmitheyMJRuddBDNikolich-ZugichJ. Age-associated alterations in CD8alpha+ dendritic cells impair CD8 T-cell expansion in response to an intracellular bacterium. Aging Cell (2012) 11(6):968–77.10.1111/j.1474-9726.2012.00867.x
23
ChougnetCAThackerRIShehataHMHenniesCMLehnMALagesCSet alLoss of phagocytic and antigen cross-presenting capacity in aging dendritic cells is associated with mitochondrial dysfunction. J Immunol (2015) 195(6):2624–32.10.4049/jimmunol.1501006
24
Grolleau-JuliusAGargMRMoRStoolmanLLYungRL. Effect of aging on bone marrow-derived murine CD11c+CD4-CD8alpha-dendritic cell function. J Gerontol A Biol Sci Med Sci (2006) 61(10):1039–47.10.1093/gerona/61.10.1039
25
WongCPMagnussonKRHoE. Aging is associated with altered dendritic cells subset distribution and impaired proinflammatory cytokine production. Exp Gerontol (2010) 45(2):163–9.10.1016/j.exger.2009.11.005
26
QianFWangXZhangLLinAZhaoHFikrigEet alImpaired interferon signaling in dendritic cells from older donors infected in vitro with West Nile virus. J Infect Dis (2011) 203(10):1415–24.10.1093/infdis/jir048
27
PandaAQianFMohantySvan DuinDNewmanFKZhangLet alAge-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 184(5):2518–27.10.4049/jimmunol.0901022
28
TesarBMWalkerWEUnternaehrerJJoshiNSChandeleAHaynesLet alMurine [corrected] myeloid dendritic cell-dependent toll-like receptor immunity is preserved with aging. Aging Cell (2006) 5(6):473–86.10.1111/j.1474-9726.2006.00245.x
29
JonesSCBrahmakshatriyaVHustonGDibbleJSwainSL. TLR-activated dendritic cells enhance the response of aged naive CD4 T cells via an IL-6-dependent mechanism. J Immunol (2010) 185(11):6783–94.10.4049/jimmunol.0901296
30
ZhaoJZhaoJLeggeKPerlmanS. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest (2011) 121(12):4921–30.10.1172/JCI59777
31
Grolleau-JuliusAHarningEKAbernathyLMYungRL. Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res (2008) 68(15):6341–9.10.1158/0008-5472.CAN-07-5769
32
TanSYCavanaghLLd’AdvigorWShackelNFazekas de St GrothBWeningerW. Phenotype and functions of conventional dendritic cells are not compromised in aged mice. Immunol Cell Biol (2012) 90(7):722–32.10.1038/icb.2011.104
33
ShawACPandaAJoshiSRQianFAlloreHGMontgomeryRR. Dysregulation of human toll-like receptor function in aging. Ageing Res Rev (2011) 10(3):346–53.10.1016/j.arr.2010.10.007
34
SapeyEGreenwoodHWaltonGMannELoveAAaronsonNet alPhosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood (2014) 123(2):239–48.10.1182/blood-2013-08-519520
35
BrubakerALRendonJLRamirezLChoudhryMAKovacsEJ. Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age. J Immunol (2013) 190(4):1746–57.10.4049/jimmunol.1201213
36
TsengCWKymePAArrudaARamanujanVKTawackoliWLiuGY. Innate immune dysfunctions in aged mice facilitate the systemic dissemination of methicillin-resistant S. aureus. PLoS One (2012) 7(7):e41454.10.1371/journal.pone.0041454
37
Alonso-FernandezPPuertoMMateIRiberaJMde la FuenteM. Neutrophils of centenarians show function levels similar to those of young adults. J Am Geriatr Soc (2008) 56(12):2244–51.10.1111/j.1532-5415.2008.02018.x
38
HazeldineJHarrisPChappleILGrantMGreenwoodHLiveseyAet alImpaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals. Aging Cell (2014) 13(4):690–8.10.1111/acel.12222
39
McLachlanJASerkinCDMorrey-ClarkKMBakoucheO. Immunological functions of aged human monocytes. Pathobiology (1995) 63(3):148–59.10.1159/000163946
40
De La FuenteM. Changes in the macrophage function with aging. Comp Biochem Physiol A Comp Physiol (1985) 81(4):935–8.10.1016/0300-9629(85)90933-8
41
FiettaAMerliniCDe BernardiPMGandolaLPiccioniPDGrassiC. Non specific immunity in aged healthy subjects and in patients with chronic bronchitis. Aging (Milano) (1993) 5(5):357–61.
42
PlowdenJRenshaw-HoelscherMEnglemanCKatzJSambharaS. Innate immunity in aging: impact on macrophage function. Aging Cell (2004) 3(4):161–7.10.1111/j.1474-9728.2004.00102.x
43
HerreroCMarquesLLloberasJCeladaA. IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice. J Clin Invest (2001) 107(4):485–93.10.1172/JCI11696
44
BoehmerEDGoralJFaunceDEKovacsEJ. Age-dependent decrease in toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J Leukoc Biol (2004) 75(2):342–9.10.1189/jlb.0803389
45
BoehmerEDMeehanMJCutroBTKovacsEJ. Aging negatively skews macrophage TLR2- and TLR4-mediated pro-inflammatory responses without affecting the IL-2-stimulated pathway. Mech Ageing Dev (2005) 126(12):1305–13.10.1016/j.mad.2005.07.009
46
MontgomeryRRShawAC. Paradoxical changes in innate immunity in aging: recent progress and new directions. J Leukoc Biol (2015) 98(6):937–43.10.1189/jlb.5MR0315-104R
47
NyugenJAgrawalSGollapudiSGuptaS. Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol (2010) 30(6):806–13.10.1007/s10875-010-9448-8
48
van DuinDMohantySThomasVGinterSMontgomeryRRFikrigEet alAge-associated defect in human TLR-1/2 function. J Immunol (2007) 178(2):970–5.10.4049/jimmunol.178.2.970
49
AgiusELacyKEVukmanovic-StejicMJaggerALPapageorgiouAPHallSet alDecreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med (2009) 206(9):1929–40.10.1084/jem.20090896
50
MolonyRDNguyenJTKongYMontgomeryRRShawACIwasakiA. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci Signal (2017) 10(509):eaan2392.10.1126/scisignal.aan2392
51
SeidlerSZimmermannHWBartneckMTrautweinCTackeF. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol (2010) 11:30.10.1186/1471-2172-11-30
52
CharaLSanchez-AtrioAPerezACuendeEAlbarranFTurrionAet alMonocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res Ther (2012) 14(4):R175.10.1186/ar3928
53
XiaLLuJXiaoW. Blockage of TNF-alpha by infliximab reduces CCL2 and CCR2 levels in patients with rheumatoid arthritis. J Investig Med (2011) 59(6):961–3.10.2310/JIM.0b013e31821c0242
54
ArnardottirHHDalliJColasRAShinoharaMSerhanCN. Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol (2014) 193(8):4235–44.10.4049/jimmunol.1401313
55
AlbrightJWAlbrightJF. Ageing alters the competence of the immune system to control parasitic infection. Immunol Lett (1994) 40(3):279–85.10.1016/0165-2478(94)00066-2
56
BradleySFKauffmanCA. Aging and the response to Salmonella infection. Exp Gerontol (1990) 25(1):75–80.10.1016/0531-5565(90)90012-Q
57
AprahamianTTakemuraYGoukassianDWalshK. Ageing is associated with diminished apoptotic cell clearance in vivo. Clin Exp Immunol (2008) 152(3):448–55.10.1111/j.1365-2249.2008.03658.x
58
NjieEGBoelenEStassenFRSteinbuschHWBorcheltDRStreitWJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging (2012) 33(1):195.e1–12.10.1016/j.neurobiolaging.2010.05.008
59
SwiftMEBurnsALGrayKLDiPietroLA. Age-related alterations in the inflammatory response to dermal injury. J Invest Dermatol (2001) 117(5):1027–35.10.1046/j.0022-202x.2001.01539.x
60
JohnsonSARozzoSJCambierJC. Aging-dependent exclusion of antigen-inexperienced cells from the peripheral B cell repertoire. J Immunol (2002) 168(10):5014–23.10.4049/jimmunol.168.10.5014
61
RileyRL. Impaired B lymphopoiesis in old age: a role for inflammatory B cells?Immunol Res (2013) 57(1–3):361–9.10.1007/s12026-013-8444-5
62
Berent-MaozBMontecino-RodriguezEDorshkindK. Genetic regulation of thymocyte progenitor aging. Semin Immunol (2012) 24(5):303–8.10.1016/j.smim.2012.04.006
63
MinHMontecino-RodriguezEDorshkindK. Effects of aging on early B- and T-cell development. Immunol Rev (2005) 205:7–17.10.1111/j.0105-2896.2005.00263.x
64
Nikolich-ZugichJ. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol (2014) 193(6):2622–9.10.4049/jimmunol.1401174
65
GeigerHde HaanGFlorianMC. The ageing haematopoietic stem cell compartment. Nat Rev Immunol (2013) 13(5):376–89.10.1038/nri3433
66
MorrisonSJWandyczAMAkashiKGlobersonAWeissmanIL. The aging of hematopoietic stem cells. Nat Med (1996) 2(9):1011–6.10.1038/nm1296-1282
67
SudoKEmaHMoritaYNakauchiH. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med (2000) 192(9):1273–80.10.1084/jem.192.9.1273
68
MillerJPAllmanD. Linking age-related defects in B lymphopoiesis to the aging of hematopoietic stem cells. Semin Immunol (2005) 17(5):321–9.10.1016/j.smim.2005.05.003
69
ShimazuTIidaRZhangQWelnerRSMedinaKLAlberola-LlaJet alCD86 is expressed on murine hematopoietic stem cells and denotes lymphopoietic potential. Blood (2012) 119(21):4889–97.10.1182/blood-2011-10-388736
70
ErgenAVBolesNCGoodellMA. Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing. Blood (2012) 119(11):2500–9.10.1182/blood-2011-11-391730
71
LabrieJEIIISahAPAllmanDMCancroMPGersteinRM. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med (2004) 200(4):411–23.10.1084/jem.20040845
72
PalmerDB. The effect of age on thymic function. Front Immunol (2013) 4:316.10.3389/fimmu.2013.00316
73
McKennaRWWashingtonLTAquinoDBPickerLJKroftSH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood (2001) 98(8):2498–507.10.1182/blood.V98.8.2498
74
RossiMIDYokotaTMedinaKLGarrettKPCompPCSchipulAHet alB lymphopoiesis is active throughout human life, but there are developmental age-related changes. Blood (2003) 101(2):576–84.10.1182/blood-2002-03-0896
75
Alter-WolfSBlombergBBRileyRL. Deviation of the B cell pathway in senescent mice is associated with reduced surrogate light chain expression and altered immature B cell generation, phenotype, and light chain expression. J Immunol (2009) 182(1):138–47.10.4049/jimmunol.182.1.138
76
StephanRPReillyCRWittePL. Impaired ability of bone marrow stromal cells to support B-lymphopoiesis with age. Blood (1998) 91(1):75–88.
77
GoronzyJJFangFCavanaghMMQiQWeyandCM. Naive T cell maintenance and function in human aging. J Immunol (2015) 194(9):4073–80.10.4049/jimmunol.1500046
78
WekslerMESzaboP. The effect of age on the B-cell repertoire. J Clin Immunol (2000) 20(4):240–9.10.1023/A:1006659401385
79
SansoniPCossarizzaABriantiVFagnoniFSnelliGMontiDet alLymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood (1993) 82(9):2767–73.
80
MattooHFaulknerMKandpalUDasRLewisVGeorgeAet alNaive CD4 T cells from aged mice show enhanced death upon primary activation. Int Immunol (2009) 21(11):1277–89.10.1093/intimm/dxp094
81
van der GeestKSAbdulahadWHTeteSMLorencettiPGHorstGBosNAet alAging disturbs the balance between effector and regulatory CD4+ T cells. Exp Gerontol (2014) 60:190–6.10.1016/j.exger.2014.11.005
82
BruunsgaardHPedersenANSchrollMSkinhojPPedersenBK. Proliferative responses of blood mononuclear cells (BMNC) in a cohort of elderly humans: role of lymphocyte phenotype and cytokine production. Clin Exp Immunol (2000) 119(3):433–40.10.1046/j.1365-2249.2000.01146.x
83
AggarwalSGuptaS. Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J Immunol (1998) 160(4):1627–37.
84
AggarwalSGollapudiSGuptaS. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J Immunol (1999) 162(4):2154–61.
85
HaynesLLintonPJEatonSMTonkonogySLSwainSL. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J Exp Med (1999) 190(7):1013–24.10.1084/jem.190.7.1013
86
LefebvreJSMaueACEatonSMLanthierPATigheMHaynesL. The aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice. Aging Cell (2012) 11(5):732–40.10.1111/j.1474-9726.2012.00836.x
87
MaueACEatonSMLanthierPASweetKBBlumermanSLHaynesL. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J Immunol (2009) 182(10):6129–35.10.4049/jimmunol.0804226
88
LefebvreJSMastersARHopkinsJWHaynesL. Age-related impairment of humoral response to influenza is associated with changes in antigen specific T follicular helper cell responses. Sci Rep (2016) 6:25051.10.1038/srep25051
89
LagesCSSuffiaIVelillaPAHuangBWarshawGHildemanDAet alFunctional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol (2008) 181(3):1835–48.10.4049/jimmunol.181.3.1835
90
RaynorJKarnsRAlmananMLiKPDivanovicSChougnetCAet alIL-6 and ICOS antagonize Bim and promote regulatory T cell accrual with age. J Immunol (2015) 195(3):944–52.10.4049/jimmunol.1500443
91
HuangMCLiaoJJBonaseraSLongoDLGoetzlEJ. Nuclear factor-kappaB-dependent reversal of aging-induced alterations in T cell cytokines. FASEB J (2008) 22(7):2142–50.10.1096/fj.07-103721
92
RosenkranzDWeyerSTolosaEGaenslenABergDLeyheTet alHigher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol (2007) 188(1–2):117–27.10.1016/j.jneuroim.2007.05.011
93
HwangKAKimHRKangI. Aging and human CD4(+) regulatory T cells. Mech Ageing Dev (2009) 130(8):509–17.10.1016/j.mad.2009.06.003
94
HoganTGosselGYatesAJSeddonB. Temporal fate mapping reveals age-linked heterogeneity in naive T lymphocytes in mice. Proc Natl Acad Sci U S A (2015) 112(50):E6917–26.10.1073/pnas.1517246112
95
WallaceDLZhangYGhattasHWorthAIrvineABennettARet alDirect measurement of T cell subset kinetics in vivo in elderly men and women. J Immunol (2004) 173(3):1787–94.10.4049/jimmunol.173.3.1787
96
NaylorKLiGVallejoANLeeWWKoetzKBrylEet alThe influence of age on T cell generation and TCR diversity. J Immunol (2005) 174(11):7446–52.10.4049/jimmunol.174.11.7446
97
KassiotisGZamoyskaRStockingerB. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J Exp Med (2003) 197(8):1007–16.10.1084/jem.20021812
98
KieperWCBurghardtJTSurhCD. A role for TCR affinity in regulating naive T cell homeostasis. J Immunol (2004) 172(1):40–4.10.4049/jimmunol.172.1.40
99
RuddBDVenturiVLiGSamadderPErteltJMWaySSet alNonrandom attrition of the naive CD8+ T-cell pool with aging governed by T-cell receptor:pMHC interactions. Proc Natl Acad Sci U S A (2011) 108(33):13694–9.10.1073/pnas.1107594108
100
WengNP. Aging of the immune system: how much can the adaptive immune system adapt?Immunity (2006) 24(5):495–9.10.1016/j.immuni.2006.05.001
101
LintonPJDorshkindK. Age-related changes in lymphocyte development and function. Nat Immunol (2004) 5(2):133–9.10.1038/ni1033
102
JohnsonSACambierJC. Ageing, autoimmunity and arthritis: senescence of the B cell compartment – implications for humoral immunity. Arthritis Res Ther (2004) 6(4):131–9.10.1186/ar1180
103
FrascaDLandinAMRileyRLBlombergBB. Mechanisms for decreased function of B cells in aged mice and humans. J Immunol (2008) 180(5):2741–6.10.4049/jimmunol.180.5.2741
104
GibsonKLWuYCBarnettYDugganOVaughanRKondeatisEet alB-cell diversity decreases in old age and is correlated with poor health status. Aging Cell (2009) 8(1):18–25.10.1111/j.1474-9726.2008.00443.x
105
MuraskoDMBernsteinEDGardnerEMGrossPMunkGDranSet alRole of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol (2002) 37(2–3):427–39.10.1016/S0531-5565(01)00210-8
106
NicolettiCYangXCernyJ. Repertoire diversity of antibody response to bacterial antigens in aged mice. III. Phosphorylcholine antibody from young and aged mice differ in structure and protective activity against infection with Streptococcus pneumoniae. J Immunol (1993) 150(2):543–9.
107
FrascaDLandinAMLechnerSCRyanJGSchwartzRRileyRLet alAging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol (2008) 180(8):5283–90.10.4049/jimmunol.180.8.5283
108
SpezialiESantiagoAFFernandesRMVazNMMenezesJSFariaAM. Specific immune responses but not basal functions of B and T cells are impaired in aged mice. Cell Immunol (2009) 256(1–2):1–5.10.1016/j.cellimm.2009.01.010
109
ZhengBHanSTakahashiYKelsoeG. Immunosenescence and germinal center reaction. Immunol Rev (1997) 160:63–77.10.1111/j.1600-065X.1997.tb01028.x
110
FrascaDVan der PutERileyRLBlombergBB. Reduced Ig class switch in aged mice correlates with decreased E47 and activation-induced cytidine deaminase. J Immunol (2004) 172(4):2155–62.10.4049/jimmunol.172.4.2155
111
WhislerRLGrantsIS. Age-related alterations in the activation and expression of phosphotyrosine kinases and protein kinase C (PKC) among human B cells. Mech Ageing Dev (1993) 71(1–2):31–46.10.1016/0047-6374(93)90033-N
112
DaileyRWEunSYRussellCEVogelLA. B cells of aged mice show decreased expansion in response to antigen, but are normal in effector function. Cell Immunol (2001) 214(2):99–109.10.1006/cimm.2001.1894
113
FrascaDRileyRLBlombergBB. Effect of age on the immunoglobulin class switch. Crit Rev Immunol (2004) 24(5):297–320.10.1615/CritRevImmunol.v24.i5.10
114
FrascaDVan der PutELandinAMGongDRileyRLBlombergBB. RNA stability of the E2A-encoded transcription factor E47 is lower in splenic activated B cells from aged mice. J Immunol (2005) 175(10):6633–44.10.4049/jimmunol.175.10.6633
115
KlineGHHaydenTAKlinmanNR. B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation. J Immunol (1999) 162(6):3342–9.
116
KlinmanNRKlineGH. The B-cell biology of aging. Immunol Rev (1997) 160:103–14.10.1111/j.1600-065X.1997.tb01031.x
117
WekslerME. Changes in the B-cell repertoire with age. Vaccine (2000) 18(16):1624–8.10.1016/S0264-410X(99)00497-1
118
HaoYO’NeillPNaradikianMSScholzJLCancroMP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood (2011) 118(5):1294–304.10.1182/blood-2011-01-330530
119
RubtsovAVRubtsovaKFischerAMeehanRTGillisJZKapplerJWet alToll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. Blood (2011) 118(5):1305–15.10.1182/blood-2011-01-331462
120
Lee-ChangCBodogaiMMoritohKOlkhanudPBChanACCroftMet alAccumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. Blood (2014) 124(9):1450–9.10.1182/blood-2014-03-563940
121
NaradikianMSHaoYCancroMP. Age-associated B cells: key mediators of both protective and autoreactive humoral responses. Immunol Rev (2016) 269(1):118–29.10.1111/imr.12380
122
Al-AttarAPresnellSRPetersonCAThomasDTLutzCT. Data correlations between gender, cytomegalovirus infection and T cells, NK cells, and soluble immune mediators in elderly humans. Data Brief (2016) 8:536–44.10.1016/j.dib.2016.06.006
123
MarttilaSJylhäväJNevalainenTNykterMJylhäMHervonenAet alTranscriptional analysis reveals gender-specific changes in the aging of the human immune system. PLoS One (2013) 8(6):e66229.10.1371/journal.pone.0066229
124
Al-AttarAPresnellSRPetersonCAThomasDTLutzCT. The effect of sex on immune cells in healthy aging: elderly women have more robust natural killer lymphocytes than do elderly men. Mech Ageing Dev (2016) 156:25–33.10.1016/j.mad.2016.04.001
125
YovelGShakharKBen-EliyahuS. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol (2001) 81(2):254–62.10.1006/gyno.2001.6153
126
BainBJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol (1996) 49(8):664–6.10.1136/jcp.49.8.664
127
Sánchez-RamónSRadiganLJoyceEYBardSCunningham-RundlesC. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol (2008) 128(3):314–21.10.1016/j.clim.2008.02.013
128
WarrenKJSweeterJMPavlikJANelsonAJDevasureJMDickinsonJDet alSex differences in activation of lung-related type 2 innate lymphoid cells in experimental asthma. Ann Allergy Asthma Immunol (2017) 118(2):233–4.10.1016/j.anai.2016.11.011
129
Les Laboratoires Servier. Lymphatic system Illustrations (2018) Available from: https://smart.servier.com/ (Accessed: March 15, 2018).
130
KleinSLFlanaganKL. Sex differences in immune responses. Nat Rev Immunol (2016) 16(10):626–38.10.1038/nri.2016.90
131
TraubSDemariaOChassonLSerraFDesnuesBAlexopoulouL. Sex bias in susceptibility to MCMV infection: implication of TLR9. PLoS One (2012) 7(9):e45171.10.1371/journal.pone.0045171
132
PisitkunPDeaneJADifilippantonioMJTarasenkoTSatterthwaiteABBollandS. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 312(5780):1669–72.10.1126/science.1124978
133
BerghoferBFrommerTHaleyGFinkLBeinGHacksteinH. TLR7 ligands induce higher IFN-alpha production in females. J Immunol (2006) 177(4):2088–96.10.4049/jimmunol.177.4.2088
134
Da SilvaJA. Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses. Ann Rheum Dis (1995) 54(1):6–16.10.1136/ard.54.1.6
135
FishEN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol (2008) 8(9):737–44.10.1038/nri2394
136
SpitzerJA. Gender differences in some host defense mechanisms. Lupus (1999) 8(5):380–3.10.1177/096120339900800510
137
MondalSRaiU. Sexual dimorphism in phagocytic activity of wall lizard’s splenic macrophages and its control by sex steroids. Gen Comp Endocrinol (1999) 116(2):291–8.10.1006/gcen.1999.7370
138
WeinsteinYRanSSegalS. Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol (1984) 132(2):656–61.
139
FurmanDHejblumBPSimonNJojicVDekkerCLThiebautRet alSystems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2014) 111(2):869–74.10.1073/pnas.1321060111
140
DeguchiKKamadaMIraharaMMaegawaMYamamotoSOhmotoYet alPostmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause (2001) 8(4):266–73.10.1097/00042192-200107000-00008
141
KumruSGodekmerdanAYılmazB. Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. J Reprod Immunol (2004) 63(1):31–8.10.1016/j.jri.2004.02.001
142
MaggioMBasariaSBleALauretaniFBandinelliSCedaGPet alCorrelation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab (2006) 91(1):345–7.10.1210/jc.2005-1097
143
SiegelRNaishadhamDJemalA. Cancer statistics for Hispanics/Latinos 2012. CA Cancer J Clin (2012) 62:10–29.10.3322/caac.21153
144
ButterworthMMcClellanBAllansmithM. Influence of sex in immunoglobulin levels. Nature (1967) 214(5094):1224–5.10.1038/2141224a0
145
KleinSLHuberS. Sex differences in susceptibility to viral infection. In: KleinSLRobertsCW, editors. Sex Hormones and Immunity to Infection. Berlin: Springer-Verlag (2009) 93–122.
146
CookIF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine (2008) 26(29–30):3551–5.10.1016/j.vaccine.2008.04.054
147
KleinSLJedlickaAPekoszA. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis (2010) 10(5):338–49.10.1016/S1473-3099(10)70049-9
148
WikbyAManssonIAJohanssonBStrindhallJNilssonSE. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20–100 years of age. Biogerontology (2008) 9(5):299–308.10.1007/s10522-008-9138-6
149
VillacresMCLongmateJAugeCDiamondDJ. Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol (2004) 65(5):476–85.10.1016/j.humimm.2004.02.021
150
AmadoriAZamarchiRDe SilvestroGForzaGCavattonGDanieliGAet alGenetic control of the CD4/CD8 T-cell ratio in humans. Nat Med (1995) 1(12):1279–83.10.1038/nm1295-1279
151
DasBRBhanushaliAAKhadapkarRJeswaniKDBhavsarMDasguptaA. Reference ranges for lymphocyte subsets in adults from western India: influence of sex, age and method of enumeration. Indian J Med Sci (2008) 62(10):397–406.10.4103/0019-5359.42725
152
StrindhallJSkogMErnerudhJBengnerMLofgrenSMatussekAet alThe inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age (Dordr) (2013) 35(3):985–91.10.1007/s11357-012-9400-3
153
LeeOJChoYNKeeSJKimMJJinHMLeeSJet alCirculating mucosal-associated invariant T cell levels and their cytokine levels in healthy adults. Exp Gerontol (2014) 49:47–54.10.1016/j.exger.2013.11.003
154
HirokawaKUtsuyamaMHayashiYKitagawaMMakinodanTFulopT. Slower immune system aging in women versus men in the Japanese population. Immun Ageing (2013) 10(1):19.10.1186/1742-4933-10-19
155
KovatsSCarrerasEAgrawalH. Sex steroid receptors in immune cells. In: KleinSLRobertsCW, editors. Sex Hormones and Immunity to Infection. Berlin: Springer-Verlag (2010) 53–92.
156
PerheentupaAHuhtaniemiI. Aging of the human ovary and testis. Mol Cell Endocrinol (2009) 299(1):2–13.10.1016/j.mce.2008.11.004
157
BainJ. Testosterone and the aging male: to treat or not to treat?Maturitas (2010) 66(1):16–22.10.1016/j.maturitas.2010.01.009
158
Neal-PerryGNejatEDickenC. The neuroendocrine physiology of female reproductive aging: an update. Maturitas (2010) 67(1):34–8.10.1016/j.maturitas.2010.04.016
159
Giefing-KröllCBergerPLepperdingerGGrubeck-LoebensteinB. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell (2015) 14(3):309–21.10.1111/acel.12326
160
GiglioTImroMAFilaciGScudelettiMPuppoFDe CeccoLet alImmune cell circulating subsets are affected by gonadal function. Life Sci (1994) 54(18):1305–12.10.1016/0024-3205(94)00508-7
161
KamadaMIraharaMMaegawaMYasuiTYamanoSYamadaMet alB cell subsets in postmenopausal women and the effect of hormone replacement therapy. Maturitas (2001) 37(3):173–9.10.1016/S0378-5122(00)00180-8
162
RaisMWilsonRMUrbanskiHFMessaoudiI. Androgen supplementation improves some but not all aspects of immune senescence in aged male macaques. GeroScience (2017) 39:373–84.10.1007/s11357-017-9979-5
163
EldermanMSovranBHugenholtzFGraversenKHuijskesMHoutsmaEet alThe effect of age on the intestinal mucus thickness, microbiota composition and immunity in relation to sex in mice. PLoS One (2017) 12(9):e0184274.10.1371/journal.pone.0184274
164
MarkleJGFrankDNMortin-TothSRobertsonCEFeazelLMRolle-KampczykUet alSex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science (2013) 339(6123):1084–8.10.1126/science.1233521
165
HaroCRangel-ZúñigaOAAlcalá-DíazJFGómez-DelgadoFPérez-MartínezPDelgado-ListaJet alIntestinal microbiota is influenced by gender and body mass index. PLoS One (2016) 11(5):e0154090.10.1371/journal.pone.0154090
166
SinghPManningSD. Impact of age and sex on the composition and abundance of the intestinal microbiota in individuals with and without enteric infections. Ann Epidemiol (2016) 26(5):380–5.10.1016/j.annepidem.2016.03.007
167
KozikAJNakatsuCHChunHJones-HallYL. Age, sex, and TNF associated differences in the gut microbiota of mice and their impact on acute TNBS colitis. Exp Mol Pathol (2017) 103(3):311–9.10.1016/j.yexmp.2017.11.014
168
YurkovetskiyLBurrowsMKhanAAGrahamLVolchkovPBeckerLet alGender bias in autoimmunity is influenced by microbiota. Immunity (2013) 39(2):400–12.10.1016/j.immuni.2013.08.013
169
BelkaidYHandTW. Role of the microbiota in immunity and inflammation. Cell (2014) 157(1):121–41.10.1016/j.cell.2014.03.011
170
GopalakrishnanVHelminkBASpencerCNReubenAWargoJA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell (2018) 33(4):570–80.10.1016/j.ccell.2018.03.015
171
GomezALuckeyDTanejaV. The gut microbiome in autoimmunity: sex matters. Clin Immunol (2015) 159(2):154–62.10.1016/j.clim.2015.04.016
172
BolnickDISnowbergLKHirschPELauberCLOrgEParksBet alIndividual diet has sex-dependent effects on vertebrate gut microbiota. Nat Commun (2014) 5:4500.10.1038/ncomms5500
173
MuellerSSaunierKHanischCNorinEAlmLMidtvedtTet alDifferences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol (2006) 72(2):1027–33.10.1128/AEM.72.2.1027-1033.2006
174
FalseyARTreanorJJTornieporthNCapellanJGorseGJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis (2009) 200(2):172–80.10.1086/599790
175
BrandãoAPDe OliveiraTCde Cunto BrandileoneMCGonçalvesJEYaraTISimonsenV. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil. Vaccine (2004) 23(6):762–8.10.1016/j.vaccine.2004.07.024
176
GoldblattDSouthernJAndrewsNAshtonLBurbidgePWoodgateSet alThe immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin Infecti Dis (2009) 49(9):1318–25.10.1086/606046
177
HainzUJeneweinBAschEPfeifferK-PBergerPGrubeck-LoebensteinB. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine (2005) 23(25):3232–5.10.1016/j.vaccine.2005.01.085
178
StarkKSchönfeldCBargJMolzBVornwaldABienzleU. Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine (1999) 17(7):844–50.10.1016/S0264-410X(98)00269-2
179
MarlovitsSStockerREfstratiouABroughtonKKaiderAVecseiVet alEffect on diphtheria immunity of combined tetanus and diphtheria booster vaccination in adults. Eur J Clin Microbiol Infect Dis (2000) 19(7):506–13.10.1007/s100960000305
180
CookIF. Sex differences in injection site reactions with human vaccines. Hum Vaccin (2009) 5(7):441–9.10.4161/hv.8476
181
NicholKLMargolisKLLindAMurdochMMcFaddenRHaugeMet alSide effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med (1996) 156(14):1546–50.10.1001/archinte.1996.00440130090009
182
GovaertTDinantGAretzKMasurelNSprengerMKnottnerusJ. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ (1993) 307(6910):988–90.10.1136/bmj.307.6910.988
183
HonkanenPOKeistinenTKiveläS-L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med (1996) 156(2):205–8.10.1001/archinte.1996.00440020115015
184
DonalisioMRRamalheiraRMCordeiroR. Eventos adversos após vacinação contra influenza em idosos, Distrito de Campinas, SP, 2000. Rev Soc Bras Med Trop (2003) 36(4):467–71.10.1590/S0037-86822003000400006
185
CouchRBWinokurPBradyRBelsheRChenWHCateTRet alSafety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine (2007) 25(44):7656–63.10.1016/j.vaccine.2007.08.042
186
BeyerWPPalacheAKerstensRMasurelN. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis (1996) 15(1):65–70.10.1007/BF01586187
187
EnglerRJNelsonMRKloteMMVanRadenMJHuangC-YCoxNJet alHalf-vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med (2008) 168(22):2405–14.10.1001/archinternmed.2008.513
188
JacksonLAAustinGChenRTStoutRDeStefanoFGorseGJet alSafety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine (2001) 19(32):4703–9.10.1016/S0264-410X(01)00225-0
189
CookIFPondDHartelG. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine (2007) 25(25):4767–74.10.1016/j.vaccine.2007.04.017
190
SočanMFrelihTJanetEPetrašTPeterneljB. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. Vaccine (2004) 22(23):3087–91.10.1016/j.vaccine.2004.02.003
191
HillebrandKBricoutHSchulze-RathRSchinkTGarbeE. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect (2015) 70(2):178–86.10.1016/j.jinf.2014.08.018
192
GergenPJMcQuillanGMKielyMEzzati-RiceTMSutterRWVirellaG. A population-based serologic survey of immunity to tetanus in the United States.N Engl J Med (1995) 332(12):761–7.10.1056/NEJM199503233321201
193
WhiteWBarnesGBarkerEGallDKnightPGriffithAet alReactions to tetanus toxoid. J Hyg (Lond) (1973) 71(02):283–97.10.1017/S0022172400022750
194
BayasJVilellaABertranMVidalJBatallaJAsenjoMet alImmunogenicity and reactogenicity of the adult tetanus–diphtheria vaccine. How many doses are necessary?Epidemiol Infect (2001) 127(03):451–60.10.1017/S095026880100629X
195
WeinbergGASzilagyiPG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis (2010) 201(11):1607–10.10.1086/652404
196
WangCSWangSTChouP. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine (2002) 20(19–20):2494–9.10.1016/S0264-410X(02)00181-0
197
Vila-CórcolesARodriguezTde DiegoCOchoaOValdiviesoASalsenchEet alEffect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002–2005 influenza periods. Vaccine (2007) 25(37):6699–707.10.1016/j.vaccine.2007.07.015
198
FlemingDWatsonJNicholasSSmithGSwanA. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989–90 using a general practice database. Epidemiol Infect (1995) 115(3):581–9.10.1017/S095026880005874X
199
NicholKLNordinJDNelsonDBMulloolyJPHakE. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med (2007) 357(14):1373–81.10.1056/NEJMoa070844
200
NicholKMargolisKWuorenmaJVon SternbergT. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med (1994) 331(12):778–84.10.1056/NEJM199409223311206
201
SonejiSMetlayJ. Mortality reductions for older adults differ by race/ethnicity and gender since the introduction of adult and pediatric pneumococcal vaccines. Public Health Rep (2011) 126(2):259.10.1177/003335491112600217
202
WiemkenTLCarricoRMKleinSLJonssonCBPeyraniPKelleyRRet alThe effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine (2014) 32(19):2198–203.10.1016/j.vaccine.2014.02.048
203
VadaszZHajTKesselAToubiE. Age-related autoimmunity. BMC Med (2013) 11:94.10.1186/1741-7015-11-94
204
RosenblumMDRemediosKAAbbasAK. Mechanisms of human autoimmunity. J Clin Invest (2015) 125(6):2228–33.10.1172/JCI78088
205
CooperGSStroehlaBC. The epidemiology of autoimmune diseases. Autoimmun Rev (2003) 2(3):119–25.10.1016/S1568-9972(03)00006-5
206
KotzinBL. Systemic lupus erythematosus. Cell (1996) 85(3):303–6.10.1016/S0092-8674(00)81108-3
207
PanditLAsgariNApiwattanakulMPalaceJPaulFLeiteMIet alDemographic and clinical features of neuromyelitis optica: a review. Mult Scler (2015) 21(7):845–53.10.1177/1352458515572406
208
QuekAMMcKeonALennonVAMandrekarJNIorioRJiaoYet alEffects of age and sex on aquaporin-4 autoimmunity. Arch Neurol (2012) 69(8):1039–43.10.1001/archneurol.2012.249
209
SteenVDOddisCVConteCGJanoskiJCasterlineGZMedsgerTAJr. Incidence of systemic sclerosis in Allegheny county, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum (1997) 40(3):441–5.10.1002/art.1780400309
210
LinosAWorthingtonJWO’FallonWMKurlandLT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol (1980) 111(1):87–98.10.1093/oxfordjournals.aje.a112878
211
WeyandCMGoronzyJJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med (2014) 371(17):1653.10.1056/NEJMcp1214825
212
OstanRMontiDGueresiPBussolottoMFranceschiCBaggioG. Gender, aging and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicine. Clin Sci (Lond) (2016) 130(19):1711–25.10.1042/CS20160004
213
BorrasCSastreJGarcia-SalaDLloretAPallardoFVVinaJ. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic Biol Med (2003) 34(5):546–52.10.1016/S0891-5849(02)01356-4
214
VinaJBorrasCGambiniJSastreJPallardoFV. Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. FEBS Lett (2005) 579(12):2541–5.10.1016/j.febslet.2005.03.090
215
EngelmannFRiveraAParkBMesserle-ForbesMJensenJTMessaoudiI. Impact of estrogen therapy on lymphocyte homeostasis and the response to seasonal influenza vaccine in post-menopausal women. PLoS One (2016) 11(2):e0149045.10.1371/journal.pone.0149045
216
ZhangJChenXZhangSZhouGXiaXLuL. Effects of transdermal estrogen therapy on expressions of estrogen receptors and T-lymphocyte apoptosis in surgically menopausal women. Cell Mol Immunol (2009) 6(4):277–83.10.1038/cmi.2009.37
217
Schulze-KoopsH. Lymphopenia and autoimmune diseases. Arthritis Res Ther (2004) 6(4):178–80.10.1186/ar1208
218
ViguierMFouereSde la SalmonierePRabianCLebbeCDubertretLet alPeripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) (2003) 82(2):82–6.10.1097/00005792-200303000-00002
219
IannoneFCauliAYanniGKingsleyGHIsenbergDACorrigallVet alT-lymphocyte immunophenotyping in polymyositis and dermatomyositis. Br J Rheumatol (1996) 35(9):839–45.10.1093/rheumatology/35.9.839
220
KirtavaZBlombergJBredbergAHenrikssonGJacobssonLManthorpeR. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjogren’s syndrome. Clin Exp Rheumatol (1995) 13(5):609–16.
221
MandlTBredbergAJacobssonLTManthorpeRHenrikssonG. CD4+ T-lymphocytopenia – a frequent finding in anti-SSA antibody seropositive patients with primary Sjogren’s syndrome. J Rheumatol (2004) 31(4):726–8.
222
KaabaSAAl-HarbiSA. Abnormal lymphocyte subsets in Kuwaiti patients with type-1 insulin-dependent diabetes mellitus and their first-degree relatives. Immunol Lett (1995) 47(3):209–13.10.1016/0165-2478(95)00088-5
223
BrandtLStenstamM. Letter: subnormal lymphocyte-counts in adult coeliac disease. Lancet (1975) 1(7913):978–9.10.1016/S0140-6736(75)92041-3
224
HeimannTMBolnickKAufsesAHJr. Prognostic significance of severe preoperative lymphopenia in patients with Crohn’s disease. Ann Surg (1986) 203(2):132–5.10.1097/00000658-198602000-00004
225
GoronzyJJLiGYangZWeyandCM. The Janus head of T cell aging – autoimmunity and immunodeficiency. Front Immunol (2013) 4:131.10.3389/fimmu.2013.00131
226
KoetzKBrylESpickschenKO’FallonWMGoronzyJJWeyandCM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 97(16):9203–8.10.1073/pnas.97.16.9203
227
WagnerUGKoetzKWeyandCMGoronzyJJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A (1998) 95(24):14447–52.10.1073/pnas.95.24.14447
228
ShaoLFujiiHColmegnaIOishiHGoronzyJJWeyandCM. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med (2009) 206(6):1435–49.10.1084/jem.20082251
229
MartensPBGoronzyJJSchaidDWeyandCM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum (1997) 40(6):1106–14.10.1002/art.1780400615
230
GoronzyJJMattesonELFulbrightJWWarringtonKJChang-MillerAHunderGGet alPrognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum (2004) 50(1):43–54.10.1002/art.11445
231
KomocsiALamprechtPCsernokEMuellerAHoll-UlrichKSeitzerUet alPeripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener’s granulomatosis. Am J Pathol (2002) 160(5):1717–24.10.1016/S0002-9440(10)61118-2
232
McKinneyEFLyonsPACarrEJHollisJLJayneDRWillcocksLCet alA CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med (2010) 16(5):586–91.10.1038/nm.2130
233
JemalASiegelRWardEHaoYPXuJQThunMJ. Cancer statistics, 2009. CA Cancer J Clin (2009) 59(4):225–49.10.3322/caac.20006
234
KanapuruBPosaniKMullerDErshlerWB. Decreased cancer prevalence in the nursing home. J Am Geriatr Soc (2008) 56(11).10.1111/j.1532-5415.2008.01864.x
235
StantaGCampagnerLCavalieriFGiarelliL. Cancer of the oldest old – what we have learned from autopsy studies. Clin Geriatr Med (1997) 13(1):55.
236
ErshlerWBLongoDL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst (1997) 89(20):1489–97.10.1093/jnci/89.20.1489
237
DiabSGElledgeRMClarkGM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst (2000) 92(7):550–6.10.1093/jnci/92.7.550
238
JedroszkaDOrzechowskaMHamouzRGorniakKBednarekAK. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer. PLoS One (2017) 12(12):e0188842.10.1371/journal.pone.0188842
239
ShariatSFSfakianosJPDrollerMJKarakiewiczPIMerynSBochnerBH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int (2010) 105(3):300–8.10.1111/j.1464-410X.2009.09076.x
240
FerraraFSchifferCA. Acute myeloid leukaemia in adults. Lancet (2013) 381(9865):484–95.10.1016/S0140-6736(12)61727-9
241
ChianCFHwangYTTerngHJLeeSCChaoTYChangHet alPanels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: their dependence on age, gender and clinical stages. Oncotarget (2016) 7(31):50582–95.10.18632/oncotarget.10558
242
SnaebjornssonPJonassonLJonssonTMollerPHTheodorsAJonassonJG. Colon cancer in Iceland-a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int J Cancer (2010) 127(11):2645–53.10.1002/ijc.25258
243
CookMBDawseySMFreedmanNDInskipPDWichnerSMQuraishiSMet alSex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev (2009) 18(4):1174–82.10.1158/1055-9965.EPI-08-1118
244
CookMBMcGlynnKADevesaSSFreedmanNDAndersonWF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev (2011) 20(8):1629–37.10.1158/1055-9965.EPI-11-0246
245
SiegelRLMillerKDJemalA. Cancer statistics, 2018. CA Cancer J Clin (2018) 68(1):7–30.10.3322/caac.21442
246
PurimOGordonNBrennerB. Cancer of the colon and rectum: potential effects of sex-age interactions on incidence and outcome. Med Sci Monit (2013) 19:203–9.10.12659/MSM.883842
247
YangYLiTNielsenME. Aging and cancer mortality: dynamics of change and sex differences. Exp Gerontol (2012) 47(9):695–705.10.1016/j.exger.2012.06.009
248
YangYKozloskiM. Sex differences in age trajectories of physiological dysregulation: inflammation, metabolic syndrome, and allostatic load. J Gerontol A Biol Sci Med Sci (2011) 66(5):493–500.10.1093/gerona/glr003
249
BarziALenzAMLabonteMJLenzHJ. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res (2013) 19(21):5842–8.10.1158/1078-0432.CCR-13-0325
250
CaiazzaFRyanEJDohertyGWinterDCSheahanK. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol (2015) 5:19.10.3389/fonc.2015.00019
251
DePinhoRA. The age of cancer. Nature (2000) 408(6809):248–54.10.1038/35041694
252
de MartelCFranceschiS. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol (2009) 70(3):183–94.10.1016/j.critrevonc.2008.07.021
253
TakahashiHOgataHNishigakiRBroideDHKarinM. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell (2010) 17(1):89–97.10.1016/j.ccr.2009.12.008
254
ParkEJLeeJHYuGYHeGAliSRHolzerRGet alDietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 140(2):197–208.10.1016/j.cell.2009.12.052
255
KhasawnehJSchulzMDWalchARozmanJHrabe de AngelisMKlingensporMet alInflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 106(9):3354–9.10.1073/pnas.0802864106
256
PalSKHurriaA. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol (2010) 28(26):4086–93.10.1200/JCO.2009.27.0579
257
MirandolaLWadeRVermaRPenaCHosiriluckNFigueroaJAet alSex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol (2015) 34(2):134–42.10.3109/08830185.2015.1018417
258
MotzerRJEscudierBMcDermottDFGeorgeSHammersHJSrinivasSet alNivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med (2015) 373(19):1803–13.10.1056/NEJMoa1510665
259
HodiFS. Improved survival with ipilimumab in patients with metastatic melanoma (vol 363, pg 711, 2010). N Engl J Med (2010) 363(13):1290.10.1056/NEJMx100063
260
RobertCLongGVBradyBDutriauxCMaioMMortierLet alNivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2015) 372(4):320–30.10.1056/NEJMoa1412082
261
RosenbergJEHoffman-CensitsJPowlesTvan der HeijdenMSBalarAVNecchiAet alAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (2016) 387(10031):1909–20.10.1016/S0140-6736(16)00561-4
262
LinPYSunLSThibodeauxSRLudwigSMVadlamudiRKHurezVJet alB7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 185(5):2747–53.10.4049/jimmunol.1000496
263
PatelJCrawfordJM. Microbiota-regulated outcomes of human cancer immunotherapy via the PD-1/PD-L1 axis. Biochemistry (2018) 57(6):901–3.10.1021/acs.biochem.7b01249
264
NishijimaTFMussHBShacharSSMoschosSJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev (2016) 45:30–7.10.1016/j.ctrv.2016.02.006
265
FerraraRMezquitaLAuclinEChaputNBesseB. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?Cancer Treat Rev (2017) 60:60–8.10.1016/j.ctrv.2017.08.003
266
LandreTTalebCNicolasPGuetzGD. Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?J Clin Oncol (2016) 34(15):3070.10.1200/JCO.2016.34.15_suppl.3070
267
ChampiatSDercleLAmmariSMassardCHollebecqueAPostel-VinaySet alHyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res (2017) 23(8):1920–8.10.1158/1078-0432.CCR-16-1741
268
BouchlakaMNMurphyWJ. Impact of aging in cancer immunotherapy the importance of using accurate preclinical models. Oncoimmunology (2013) 2(12):e27186.10.4161/onci.27186
269
ClaytonJA. Applying the new SABV (sex as a biological variable) policy to research and clinical care. Physiol Behav (2018) 187:2–5.10.1016/j.physbeh.2017.08.012
Summary
Keywords
sex, sex hormones, immunity, autoimmunity, cancer, vaccines, immunotherapy, checkpoint blockade
Citation
Gubbels Bupp MR, Potluri T, Fink AL and Klein SL (2018) The Confluence of Sex Hormones and Aging on Immunity. Front. Immunol. 9:1269. doi: 10.3389/fimmu.2018.01269
Received
19 March 2018
Accepted
22 May 2018
Published
04 June 2018
Volume
9 - 2018
Edited by
Virginia Rider, Pittsburg State University, United States
Reviewed by
Piergiuseppe De Berardinis, Istituto di biochimica delle proteine (IBP), Italy; Paola Italiani, Consiglio Nazionale Delle Ricerche (CNR), Italy
Updates
Copyright
© 2018 Gubbels Bupp, Potluri, Fink and Klein.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Melanie R. Gubbels Bupp, melaniegubbelsbupp@rmc.edu
Specialty section: This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.